RecruitingPhase 1NCT03743298

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Studying Dendritic cell tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aivita Biomedical, Inc.
Principal Investigator
Robert O Dillman, MD
Aivita Biomedical, Inc.
Intervention
AV-MEL-1(drug)
Enrollment
20 target
Eligibility
18 years · All sexes
Timeline
2021 – 2026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03743298 on ClinicalTrials.gov

Other trials for Dendritic cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Dendritic cell tumor →

← Back to all trials